CURRENT PHARMACEUTICAL LETTERS AND REVIEWS (CPLR)

Available online on http://www.cplr.in/
Current Pharmaceutical Letters and Reviews 2024; 01(01); 01-10

Review

Drug Response in Gastric Cancer: A Comprehensive Review of Progression Mechanisms

Kapil Kumar*, Smriti Gohri, Divya Patak

Department of Pharmacy, IIMT College of Medical Sciences, IIMT University, O-Pocket, Ganganagar, Meerut, 250001, U.P., India

Abstract:

There were over one million new instances of gastric cancer worldwide, making it a significant unmet clinical concern in 2018. This kind of malignant growth is the fourth most pervasive in guys and the seventh most normal in ladies. Numerous pathogenic diseases, like Helicobacter pylori (H. pylori) and Epstein Barr virus (EBV), have been related with a critical part of stomach malignant growth cases. A significant level of stomach malignant growth has been kept away from on the grounds that to measures being taken to stop the development of the infection, like the evacuation of the H. pylori microbes. Therapies accessible today have made this disease more straightforward to deal with; for stage IA and IB cancers that have gone through a medical procedure, the 5-year endurance rate is somewhere in the range of 60% and 80%. Then again, the hopeless 5-year endurance rate for patients with stage III diseases having a medical procedure fluctuates from 18% to half concurring on the dataset. These numbers show that more potent molecularly based therapeutic approaches are required. This study covers the molecular profile of gastric cancers, as well as the advantages and disadvantages of the current treatment targets, emerging targets, and fresh biomarkers.

Keywords: *Drug Response, Progression Mechanisms, Review, Gastric Cancer*

Received: 25-05-2024 / Revised: 23-06-2024 / Accepted: 03-07-2024

Corresponding Author: Kapil Kumar
Email: kapilkumarer123@gmail.com

Conflict of interest: Nil

1. INTRODUCTION

Despite advancements in medical diagnosis and treatment, stomach cancer still has the fourth-highest morbidity rate among all cancer types [1]. Furthermore, it is the second leading cause of cancer-related deaths worldwide. East Asian countries have a high rate of stomach cancer, including China, Japan, and Korea. Only lung cancer remained the most frequent and deadly cancer; stomach cancer came in second. An estimated 700,000 new cases are reported annually, with the majority occurring in rural areas. However, many instances in China are at a late stage due to the disease's subtle symptoms and lack of early detection screening, making therapeutic therapies more challenging. Patients with advanced-stage stomach tumors would benefit more from combination therapy consisting of surgery, chemotherapy, radiation, and target therapy [2]. One of the primary adjunctive techniques in treatment is chemotherapy; however, the emergence of drug resistance limits its efficacy and may result in treatment failure. We must investigate the mechanisms underlying chemotherapy resistance and come up with solutions in order to address this issue [3].

Chemotherapy-induced medication resistance involves intricate systems [5]. Based on our understanding, we categorize them into the following seven aspects: Lower the effective concentration of intracellular medications; Modify the targets of drugs; Damage repair dysfunction of DNA; Modify apoptosis and autophagy; Modify the microenvironment of the tumor; Extracellular vesicles and macropinocytosis; and MicroRNAs and LncRNAs. Even while our understanding of the molecular mechanisms underlying drug resistance has advanced significantly, there is still a paucity of practical methods for identifying and managing chemotherapy resistance in clinical settings [6]. This

article aims to provide an overview and analysis of the advancements made in the field of chemotherapy research for stomach cancer, which may help us find new ways to address this issue.



Figure 1: Gastric Cancer [4]

2. GASTRIC CANCER DEVELOPMENT IS ATTRIBUTED TO A VARIETY OF CAUSES

Helicobacter pylori (H. pylori) and the Epstein Barr virus (EBV) are only two of the numerous pathogenic viruses that are liable for most of recently analyzed occurrences of gastric disease. These two main pathogens use a variety of intracellular mechanisms to affect the course of disease.

2.1. Helicobacter Pylori

The greater part of the total populace is burdened with gastric disease because of the normal pathogenic bacterium H. pylori. It is ordered as a class I cancer-causing agent, and in a little extent of impacted people, the sickness advances typically. Peptic ulcer development is influenced by the pathogenic CagA protein, which is expressed by 70% of US patients and 100% of Asian patients. East Asian demographic polymorphisms, such as the EPIYA motif, have an impact on the development of stomach cancer, especially in the Korean population. Peptidoglycan secretion by H. pylori has been linked to cancer formation and chronic inflammation. Furthermore, H. pylori has the ability to inhibit T-cell reactions, which permits lesions to develop with little to no immunological reaction. Reversing and detecting the illness can help stop it from coming again.

Table 1: Summary of Studies on Gastric Cancer

AUTHORS	SUBJECT	RESULT
Liang, Y. X., Deng, J. Y., Guo, H. H., et al. (2013) [7]	To clarify the significance of age in the prognosis of gastric cancer and determine the best course of care for older patients with gastric cancer	The study categorized patients into younger, middle-aged, and elderly groups, identified prognostic factors, and stratified age impact on survival, cancer-specific survival, lymphadenectomy extent, and postoperative chemotherapy.
Petrelli, F., Berenato, R., Turati, L., et al. (2017) [8]	Meta-analysis to look into the relationship between patients' prognosis and histology based on the Lauren classification in stomach cancer patients	Diffuse-type histology is linked to worse prognosis in gastric cancer patients, regardless of location, disease type, or adjuvant therapy exposure. Histology could be a useful prognostic marker for future clinical trials.
Rugge, M., Fassan, M., & Graham, D. Y. (2015) [9]	Overview of gastric cancer and its major causes, risk factors, and challenges in diagnosis and treatment	With advanced cases and few available treatments, gastric cancer ranks third in the world for cancer-related deaths. Helicobacter pylori, Epstein-Barr virus, and genetic factors are major contributors. Primary prevention is becoming more and more advised.
Han, J. P., Hong, S. J., & Kim, H. K. (2014) [10]	Assessment of the clinicopathological features and the long-term consequences of mixed adenocarcinoma in the early stages of gastric cancer	Compared to other histological types, mixed adenocarcinoma, which was discovered as early gastric cancer (EGC) during endoscopic submucosal dissection (ESD), has a higher risk of local recurrence and has been found to be an independent prognostic factor.

Stahl, P., Seeschaaf, C., Lebok, P., et al. (2015) [11]	investigation of predictive gene changes and the intra-tumor heterogeneity of known and putative target genes in gastric cancer	A tissue microarray containing tissue cores from 9 primary gastric cancer areas and 113 lymph node metastases was used to assess amplification of HER2, EGFR, CCND1, and MYC. Intra-tumor heterogeneity was found for biomarkers in gastric cancer, particularly in low-level amplification.

Eliminating the H. pylori infection in individuals with stomach ulcers may lower their chance of acquiring gastric cancer, according to a meta-analysis of 22 research. The study found that individuals who had eradication therapy had a reduced incidence of stomach cancer than those who did not. The effect of elimination on the prognosis of stomach cancer was also assessed in this study. The study highlights how important it is to treat stomach cancer by getting rid of H. pylori.

2.2. Epstein Barr Virus

In 10% of cases, the Epstein Barr virus (EBV) has been shown to affect the course of stomach cancer. Cells with low expression of the cluster of differentiation 21 marker (CD21) are not susceptible to infection by the virus, but cells with high CD21 expression are. Through endocytosis, external EBV virons coated with IgA can attach to the IgA human cellular receptor, enabling the virus to enter the cell and become integrated [12]. EBV integration also takes place via the virus's gH/gL and gp42 ligands, which attach to B-lymphocytes' HLA class II surfaces. Viral fusion and infection are caused by interactions between the host β2 integrin protein and the EBV BMFR2 protein.

2.3. Non-Pathogenic Influences

A less than stellar eating routine, smoking, unnecessary salt admission, and hereditary irregularities in the E-cadherin (CDH1) quality are a portion of the gamble factors for gastric cancer. Occurrence rates for hereditary diffuse gastric cancer (HDGC) can reach half, influencing 3% of the populace. Gastric cancer cases are also influenced by environmental and lifestyle factors, such as smoking, eating a poor diet, and consuming a lot of salt. A higher risk of developing stomach cancer has been associated with high consumption of red and processed meats. A tiny percentage of people can benefit from changes in lifestyle, such as consuming hot meals, eating a midnight snack, and tampering with genes that control circadian rhythm. Additionally, smoking raises the chance of stomach cancer, namely the diffuse or cardia subtype [13]. The majority of the time, resistance to chemotherapy is widespread; further research is required to understand how to treat and overcome this resistance.

3. GASTRIC CANCER TREATMENT BASED ON DISEASE STAGE

As of this moment, there is no highest quality level therapy for stomach or esophageal junction (GEJ) cancer. The sickness stage, the presence of biomarkers, and the specialist's suggested game-plan are the essential variables considered while picking a therapy plan. Therapy decisions for gastric cancer have been incredibly worked on by the utilization of the cancer staging system (cTNM) created by the American Joint Committee on Cancer (AJCC).



Figure 2: Treatment Of Gastric Cancer Based on Disease Stage [14]

This staging system demonstrates whether far off metastases are available (M), whether the growth has attacked the stomach wall layers (T), and whether lymph hubs have been involved (N).

3.1. Surgical Intervention

Tumor resection is the main treatment strategy for individuals with gastric cancer in the early stages of their illness. Surgical techniques for this purpose can include distal esophagectomy and endoscopic mucosal resection. The location and depth of the tumor's infiltration determine the sort of surgery that is needed [15]. The US has a high rate of older

gastric cancer patients, therefore it's critical to optimize surgical intervention and take comorbidities into account. According to a recent study, individuals who received laparoscopic assisted gastrectomy had a decreased chance of complications.

3.2. Cytotoxic Therapies

For Gastric cancer, medical procedure is the only therapy that can be healing, yet chemotherapy might increment endurance. Adjuvant therapy expanded the endurance paces of Stage II and III patients when contrasted with a medical procedure alone, as indicated by a huge scope study. Therapy options for metastatic gastric cancer in the US range from combinations in doublet or trios to cytotoxic monotherapy as first line therapy. The National Comprehensive Cancer Network (NCCN) rules propose perioperative chemotherapy or preoperative chemoradiotherapy for privately progressed ailment. How much preoperative chemotherapy regulated has expanded beginning around 2005. A multimodality therapy to privately progressed gastric cancer further develops by and large endurance contrasted with a medical procedure alone, as demonstrated by the Wizardry and SWOG INT-0116 preliminaries [16]. Combinations of doublet or trio chemotherapeutic regimens have been utilized in gastric cancer therapy since the 1970s, and the outcomes have been consistently better. Following the uplifting results of the stage III FLOT4-AIO preliminary, the FLOT (docetaxel, 5FU, leucovorin, and oxaliplatin) has turned into the suggested perioperative routine.

Table 2: Studies on Gastric Cancer Classification, Prognosis, and Prevention

AUTHORS	SUBJECT	RESULT
Prashanth, R., & Barsouk, A. (2019) [17]	Epidemiology and prevention of gastric cancer	Gastric cancer is a prevalent and deadly global disease, particularly among older males, with 783,000 deaths in 2018. Its incidence and mortality rates vary by region and are influenced by dietary habits and Helicobacter pylori infection. Prevention strategies include diet, smoking cessation, exercise, and genetic testing.
Chen, Y. C., et al. (2016) [18]	Prognostic significance of Lauren's classification in gastric cancer patients	Lauren's classification is a useful histological tool for gastric cancer, with intestinal type patients showing better 5-year survival rates. These patients are older, predominantly male, have smaller tumors, are well-differentiated, and have less advanced tumor characteristics.
Hu, B., et al. (2012) [19]	New classification of gastric cancers and the application of molecular testing	This article discusses the advancements in gastric cancer classifications, focusing on histological features, genotypes, and molecular phenotypes, which can aid in early diagnosis, prevention, and treatment, thereby improving patient management.
Li, Y., et al. (2018) [20]	Comparison of clinicopathologic features and prognosis based on the revised Lauren's classification in gastric cancer patients	The revised Lauren's classification of gastric cancer identifies four subgroups: intestinal, diffuse, solid, and mixed. A study of 166 cases revealed varying clinicopathologic features and prognosis among these subtypes. Intestinal type patients were older, predominantly male, and more often found in the antrum. Diffuse type patients were younger, solid type had larger tumors, and mixed type patients had significantly worse survival outcomes.
Miaozhen, Q., et al. (2014) [21]	Prognostic significance of Lauren-classification and HER2 status in gastric cancer patients	An investigation of 838 gastric cancer patients surveyed the prognostic worth of a combination of Lauren-classification and HER2 status (L-H status). The review tracked down tremendous contrasts in middle generally endurance among gatherings, with HER2 status being an autonomous prognostic figure gastrointestinal sort and stage I+II patients. L-H status was a free prognostic figure all stages, with HER2 negative status related with better endurance results.

In research containing 716 patients with stomach and gastroesophageal junction adenocarcinomas that were resectable, it was found that FLOT fundamentally worked on the middle by and large endurance. For patients with resectable stomach and esophageal cancer who are in great execution status and have no conflicting comorbidities, FLOT has arisen as the backbone perioperative therapy. FOLFOX or CAPOX are managed perioperatively for patients with not great execution status or clinical issues that might impede their capacity to endure FLOT.

Studies demonstrating a more prominent tiny negative edge however no advantage in the neurotic complete response have provoked ongoing endeavors to further develop FLOT. Trastuzumab and Pertuzumab added to FLOT brought about a considerable expansion in the serious neurotic response rate and hub adverse result, as demonstrated by the PETRARCA study [22]. In any case, this study won't continue to stage III because of expanded harmfulness.

First-line chemotherapy for metastatic patients incorporates a platinum-based drug in addition to a cytotoxic substance like 5FU; these regimens are generally FOLFOX or CAPOX, no matter what trastuzumab (in the event that HER2 is overexpressed). Since May 2017, pembrolizumab plays had a huge impact in the therapy of gastric cancer. In June 2020, the FDA endorsed pembrolizumab for use in all strong growths with high tumor mutational burden (TMB-H). Contingent upon earlier medicines, irinotecan may likewise be utilized as a third or additional treatment [23].

The 5-year endurance pace of stomach cancer in the US has dynamically expanded to 31% thanks to headways in chemotherapy regimens.

3.3. Targeted Therapies

There is general arrangement that greater headway is expected, notwithstanding the way that using the ongoing designated specialists for gastric cancer (pembrolizumab, trastuzumab, and Ramucirumab) further develops operating system. An outline of novel designated medicines and little particle inhibitors going through pre-clinical or clinical examination will be given in this section.

3.4. Tyrosine Kinase Inhibitors (TKIs)

Imatinib, Vandetanib, and Sunitinib are tyrosine kinase inhibitors (TKIs) that are right now being scrutinized for use in designated therapy. These medications impact major cell endurance systems including HER2, EGFR, VEFG, and MET by impeding the phosphorylation or dephosphorylation of the tyrosine kinase protein overflow. Having said that, the discoveries on stomach cancer are not exceptionally encouraging [24]. In a stage II clinical preliminary of metastatic gastric cancer, the strong inhibitor imatinib, which is helpful in treating CML and Essences, neglected to demonstrate any clinical viability or response. By and large endurance was 6.8 months when contrasted with standard of care, and there was no significant therapeutic benefit with sunitinib, a VEFG inhibitor. Clinical trials with the VEGFR2 antibody ramucirumab have improved gastric cancer outcomes. Due to inadequate patient accrual, the Phase I clinical trials of venetanib, a multi-kinase VEGFR inhibitor, were prematurely halted. Researchers are also looking at the effects of preclinical TKIs on gastric cancer, such as AZD4547 and Tucatinib. Additional research is required to determine which gastric cancer patient subgroups are good candidates for TKI treatment and to discover new, effective therapeutic targets.

3.5. Cell Structure Remodeling Therapies

Inhibitors of cytoskeleton components are another class of targeted therapeutics that are presently under investigation. The suppression of cytoskeleton components was discovered to trigger apoptosis and promote cellular death in the poorly differentiated (diffuse) gastric tumors. Taxol drugs, which suppress cytoskeleton components like microtubules, are somewhat successful in controlling this disease, thus this idea is not new. A portion of the objectives being researched incorporate cytoskeletal components such tubulins, myosin, kinesins, and dynamins. The tubulin inhibitor T900607 is as of now being scrutinized in Stage I clinical preliminaries for GEJ cancer. It ties irreversibly to colchicine restricting locales [25]. Albeit this medication showed no portion restricting poison levels, it made a few poison levels the heart. Additional examination is expected to decide whether this routine would beat taxol drugs like paclitaxel or docetaxel. Additionally, pre-clinical examinations have demonstrated that microtubule associated proteins (MAPs) are a viable enemy of cancer approach. For instance, a Guide called FAM83 was found to be overexpressed in gastric cancer patients, and eliminating this protein made the growths contract. Monastrol and comparative medications block Eg5, a protein engaged with shaft formation; this therapeutic methodology is successful in prompting a response even in cells that are impervious to taxol attributable to upgraded drug efflux or other tubulin alterations. Inhibition of MAP2, tau, and MAP4 additionally created this result. There has been late interest in investigating likely new roads for focusing on cell division in gastric cancer research, away from normally happening taxol synthetic compounds that are helpless to cell opposition systems.

Targeting of DNA Damage Repair Proteins

Some gastric cancer patients have mutations in proteins that repair DNA damage. As an illustration, the TCGA publically available database indicates that approximately 14% to 20% of gastric cancer patients carry mutations in

ATM, BRCA1, BRCA2, and ATR. A malignant phenotype develops when a normally functioning cell becomes unable to repair damaged DNA because to mutations in these proteins. Furthermore, these mutations in turn cause the cell to acquire other mutations [26]. Although alkylating chemicals like nitrogen mustards are used to target DNA repair proteins, their effectiveness has been found to be low and several resistance mechanisms have been discovered.

A new class of compounds called poly (ADP-ribose) polymerase (PARP) inhibitors is currently being studied for its potential use in treating gastric cancer. These inhibitors provide a unique approach to targeting the DNA repair mechanism. A significant physiological function of PARP is chromatin restricting and the enrollment of various DNA harm response proteins (such XRCC1/ATM/MRE11) to DNA harm locales with the goal that the cell can complete fix exercises proficiently. Ovarian, bosom, and prostate cancers have all made therapy progress by hindering PARP. Inhibitors of PARP1 forestall the response to single-abandoned DNA harm. Parp inhibition by means of synthetic lethality is compelling against cancers brought about by mutations in BRCA and twofold abandoned DNA fix proteins [27]. Gastric cancer patients are undergoing pre-clinical and clinical trials for the PARP inhibitors niraparib, rucaparib, and olaparib. A recent study in an Asian gastric cancer cohort looked at the sensitivity of patients with ATM defects to PARP inhibition using Olaparib. Overall survival did not achieve a statistically significant level, which is the primary aim. In line with these findings, another clinical trial found that patients with low ATM activity tended to benefit from a combination of Olaparib and paclitaxel, rather than just paclitaxel, but that the combination had no positive effect on overall survival.

As a standalone treatment, PARP inhibitors don't appear to do much good, but a phase II research is now underway to see how well they work when combined with olaparib, the current gold standard. Hypoxic mimetic medications impact homologous recombination pathways in gastric cancer cells, making them more defenseless to PARP inhibitors; this finding offers strong logical help for the utilization of this combination. Since gastric cancer has had less accomplishment than bosom or ovarian cancer as far as PARP inhibition, more investigation into this component is obviously required. This is valid whether the objective is single specialist or combination therapy.

Additionally, MHY440 and APG-115, two other preclinical synthetic compounds with expected jobs in cell fix, are being trying. In a way dependent on reactive oxygen species (ROS), the topoisomerase inhibitor MHY440 has been found to really restrain the DNA harm response pathway and upgrade apoptotic demise [28]. In a board of gastric cancer cell lines, the MDM2-p53 inhibitor APG-115 expanded radiosensitivity in p53 wild sort gastric cells by killing off multiplying cells and expanding their aversion to radiation. To prevent ERK2 from typically dephosphorylating and initiating, another synthetic called BCI hydrochloride allosterically represses Dusp6, a negative input system that intercedes ERK related proteins. Dusp6 isn't straightforwardly engaged with DNA fix, yet it has been demonstrated that restraining this protein can beat resilience to cisplatin, a cytotoxic medication that harms DNA fix. This shows that Dusp6 might play other parts in DNA fix. It very well might be beneficial to research AZD7648 as a potential new therapy option for gastric cancer, as it restrained non-homologous end joining (NHEJ) and expanded responsiveness of cellular breakdown in the lungs cell lines to radiation, chemotherapy, and Olaparib. Seeing if these medications have an endurance advantage will require more clinical and preclinical exploration later on.

- **Immunotherapy**

The job of resistant regulation in gastric cancer is additionally being explored. Stage II and III gastric cancer patients had a lower generally speaking endurance rate when PD-L1 expression was connected with in a resistant board examination of a partner of gastric cancer patients. Overexpression of the cancer cell surface marker PD-L1 keeps gastric cancers from being distinguished by the insusceptible system since it forestalls Lymphocyte related focusing on. According to the FORCE1 study, a significant number of Chilean patients with stomach cancer may be good candidates for immunotherapy after testing individual populations. The high incidence of microsatellite instability due to stomach cancer carcinogenesis caused by the Epstein-Barr virus in this area may be a contributing factor. Despite the fact that only a small fraction of gastric cancer patients are found to have the Epstein-Barr virus as their causative agent, those patients with this disease have a better chance of survival than those without the virus, and they may even have an even better chance of survival after 5 years with immunotherapy [29]. The stage II Feature 059 preliminary found that the PD-L1 inhibitor pembrolizumab (Keytruda) was successful in expanding response rates to 11.6% from 2.3% in the control arm, prompting the medication's endorsement for third-line utilization in gastric cancer therapy. Immunotherapy might be the most ideal option for the around 40% of patients whose gastric cancers express elevated

degrees of PD-L1, since this gathering has more awful in general endurance results notwithstanding decreased frequency of metastatic illness. Because of the extraordinary heterogeneity of gastric cancer, which will be examined in more detail later on, additional exploration is expected to decide if subsets of gastrointestinal populations with growths that express PD-L1 at significant levels are more defenseless to PD-L1 inhibition.

Other treatment options exist, including as PD1 inhibition, in addition to PD-L1 immunotherapy. Immune T-cells that look for cancer have a marker called PD1, and when it binds to PD-L1 on other cells, it destroys them. As we've already established, PD-L1 expression is abundant in cancer cells, and the immune system uses this finding to keep cancer at bay. Additionally, nivolumab, which inhibits PD1, is undergoing clinical testing. A phase 3 research indicated that this immunotherapy improved 12-month survival rates, suggesting it could be an additional immunotherapeutic option for patients with gastric cancer [30]. Additionally, a phase I/II clinical trial indicated that the standard-of-care treatment for gastric cancer, Ramucirumab, was more effective when PD1 inhibition was present. additional than the PD1/PD-L1 axis, additional immune system markers are the subject of preclinical research, such as tumor-infiltrating lymphocyte (TIL) therapy, interferons, interleukins, and car T cell therapy.

Interferons, a family of glycoproteins secreted in reaction to bacterial or viral infections, including interferon gamma (IFN-y), was discovered to be elevated in the stomach mucosa following an H. pylori infection. It was discovered that IFN-y promotes carcinogenesis by increasing NF-kB activation [31]. One pro-inflammatory secretory protein that fuels the formation and advancement of gastric cancer through several paracrine signaling pathways is interleukin-6 (IL-6), which is mostly discharged by leukocyte cells. Studies in gastric cancer models revealed that the monoclonal antibody tocilizumab, which inhibits IL-6, induced chemotherapy-directed apoptosis. Extensive research is being conducted to better understand the function of interleukins like IL-32, IL17A, and IL-11 in gastric cancer. However, there is still a long way to go before targeted therapies can be developed and used for this disease type as a whole, especially in subsets of patients like those with EBV-associated or microsatellite instability (MSI).

One novel approach is to detect and combat stomach cancer by means of T-cell receptor treatment, which is being used and manipulated. A new form of treatment called chimeric antigen receptor (Car T) therapy is presently being investigated for solid tumors like gastric cancer, in addition to a number of liquid malignancies. Vehicle Lymphocytes, which explicitly target gastric cancer-related receptors known as claudin 18.2 or EpCAM, were demonstrated to be exceptionally powerful in pre-clinical and Stage I open name clinical exploration against gastric cancer and pancreatic ductal adenocarcinoma, as per a new clinical review. Lymphocytes that penetrate tumors are called tumor infiltrating lymphocytes (TILs). These cells are tracked down in stomach cancer and are for the most part used to conjecture how well patients will respond to adjuvant chemotherapy, yet they can likewise be utilized as a therapeutic other option. Extraction of tumor-occupant TILs that can distinguish dangerous cells, treatment of these cells with the IL-2 cytokine, and resulting expansion and reinfusion of these cells into the body have been demonstrated to be successful in strong malignancies like melanoma [32]. Infusion of autologous TILs and concurrent therapy with fludarabine and cyclophosphamide are being concentrated on in Stage II clinical examinations for a scope of strong malignancies, including gastric cancer.

A moderately new area of study is the chance of fitting immunological therapy ways to deal with stomach cancer. Heaps of information focuses to the likelihood that this therapy could help a subset of gastric cancer patients. The perceived heterogeneity of gastric cancer cases requires additional examination into gastric cancer subpopulations to distinguish in danger people [33].

4. DRUG RESPONSE IN GASTRIC CANCER: A BEACON OF HOPE IN TREATMENT

Despite its difficulties, gastric cancer responds differently to different treatments. Oncologists can tailor therapy to ensure the best possible outcome for their patients by comprehending these responses [34]. Here is a more in-depth look at this important aspect of managing gastric cancer:

4.1. Factors Influencing Drug Response:

- **Cancer Subtype:** There are various subtypes of gastric cancer, including diffuse, intestinal, and others. There are varying degrees of susceptibility to particular drugs or drug combinations in each subtype [35]. For example, digestive sort gastric disease for the most part answers better to chemotherapy regimens like FLOT (fluorouracil, leucovorin, oxaliplatin, docetaxel) contrasted with the diffuse kind.

- **Genetic Landscape:** Cancer cells' responses to treatment are significantly influenced by the presence of particular mutations. HER2-positive cancers, for instance, show a noticeable reaction to designated treatment with trastuzumab, which benefits from the overexpression of the HER2 protein [36]. Alternately, growths coming up short on this transformation probably won't profit from this medication.
- **Treatment Regimen:** A drug's efficacy depends not only on the drug itself but also on how much it is taken and when it is taken. Chemotherapy with a single agent may not be as effective as well-designed combination therapies, in which drugs with different mechanisms of action work together.

4.2. Types of Drugs and their Impact:

- **Chemotherapy:** Drugs like fluorouracil and cisplatin, which target cancer cells that divide rapidly, are the foundation of treatment for gastric cancer. Response rates vary according to the treatment plan and characteristics of the tumor.
- **Targeted Therapy:** These medications target explicit particles that fuel disease development. Trastuzumab, for example, focuses on the HER2 protein, prompting further developed reaction rates in HER2-positive cancers [37].
- **Immunotherapy:** This strategy makes use of the immune system's ability to identify and destroy cancer cells. Immunotherapy, which is still in its infancy in gastric cancer, holds promise for patients who do not respond well to conventional treatments.

4.3. Predicting Response for Personalized Medicine:

- **Biomarker Analysis:** Analyzing growth tests for explicit transformations or protein articulations can give important bits of knowledge into potential medication reaction. This data engages oncologists to pick medicines with the most elevated probability of progress for a specific patient.
- **Pharmacogenomics:** This field investigates how an individual's qualities impact their reaction to prescriptions. By knowing a person's genetics, doctors may be able to modify chemotherapy regimens or anticipate potential side effects, resulting in more individualized treatment plans.

4.4. Challenges and Future Directions:

- **Tumor Heterogeneity:** A variety of cells with varying genetic profiles make up tumors frequently. Because different subpopulations of the tumor may respond to treatment in different ways, this heterogeneity can result in unpredictability in drug responses.
- **Optimizing Treatment Strategies:** Treatment protocols that are tailored to a patient's unique tumor characteristics and genetic profile are the subject of ongoing research. This customized approach holds monstrous potential for augmenting reaction rates and limiting incidental effects.

Drug reaction in gastric malignant growth is a complicated exchange between cancer science, therapy plan, and individual patient variables [38]. We can move toward a future in which gastric cancer treatment is more patient-centered and effective by deciphering these complexities and implementing personalized medicine strategies.

5. CONCLUSION

Understanding drug response mechanisms offers a glimmer of hope in the treatment of gastric cancer, despite its persistent challenges [39]. Gastric malignant growth presents in assorted subtypes, each answering distinctively to different treatment modalities. Trastuzumab and other targeted therapies like immunotherapies may or may not be effective depending on genetic factors. Pharmacogenomics and biomarker analysis can be used to create personalized treatment plans for each patient. Notwithstanding, difficulties, for example, cancer heterogeneity endure, requesting progressing examination to refine therapy techniques. However, we pave the way for more efficient and patient-centered gastric cancer care by delving into the intricate interaction of tumor biology, treatment design, and patient-specific factors [40].

REFERENCES

1. *Bae, J. M., & Kim, E. H. (2016). Epstein-Barr Virus and Gastric Cancer Risk: A Meta-analysis with Meta-regression of Case-control studies. J Prev Med Public Health, 49(2), 97–107. DOI: 10.3961/jpmph.15.068*
2. *Wroblewski, L. E., Peek, R. M., & Wilson, K. T. (2010). Helicobacter pylori and Gastric Cancer: Factors that Modulate Disease Risk. Clinical Microbiology Reviews, 23(4), 713–739. DOI: 10.1128/CMR.00011-10.*

3. *Conteduca, V., Sansonno, D., Lauletta, G., Russi, S., Ingravallo, G., & Dammacco, F. (2012). H pylori infection and gastric cancer: State of the art. International Journal of Oncology. DOI: 10.3892/ijo.2012.1701.*
4. *Rick, J. R., Goldman, M., Semino-Mora, C., Liu, H., Olsen, C., Rueda-Pedraza, E., ... Dubois, A. (2010). In situ expression of cagA and risk of gastroduodenal disease in Helicobacter pylori infected children. J Pediatr Gastroenterol Nut, 50(2), 167–172. DOI: 10.1097/MPG.0b013e3181bab326*
5. *Hatakeyama, M. (2004). Oncogenic mechanisms of the Helicobacter pylori CagA protein. Nat Rev Cancer, 4(9), 688–694. DOI: 10.1038/nrc1433.*
6. *Jones, K. R., Joo, Y. M., Jang, S., Yoo, Y. J., Lee, H. S., Chung, I. S., ... Cha, J. H. (2009). Polymorphism in the CagA EPIYA Motif Impacts Development of Gastric Cancer. Journal of Clinical Microbiology, 959–968. DOI: 10.1128/JCM.02330-08.*
7. *Liang, Y. X., Deng, J. Y., Guo, H. H., et al. (2013). Characteristics and prognosis of gastric cancer in patients aged ≥ 70 years. World J Gastroenterol, 19(39), 6568–6578. doi: 10.3748/wjg.v19.i39.6568*
8. *Petrelli, F., Berenato, R., Turati, L., Mennitto, A., Steccanella, F., Caporale, M., ... Di Bartolomeo, M. (2017). Prognostic value of diffuse versus intestinal histotype in patients with gastric cancer: a systematic review and meta-analysis. Journal of Gastrointestinal Oncology, 8(1).*
9. *Rugge, M., Fassan, M., & Graham, D. Y. (2015). Epidemiology of Gastric Cancer. Gastric Cancer, 23–34.*
10. *Han, J. P., Hong, S. J., & Kim, H. K. (2014). Long-term outcomes of early gastric cancer diagnosed as mixed adenocarcinoma after endoscopic submucosal dissection. JGH, 30(2), 316–320. DOI: 10.1111/jgh.12838.*
11. *Stahl, P., Seeschaaf, C., Lebok, P., et al. (2015). Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer. BMC Gastroenterol, 15, 7. DOI: 10.1186/s12876-015-0231-4.*
12. *Kim, K. E. (2003). Gastric Cancer in Korean Americans: Risks and reductions. Korean Korean Am Stud Bull, 13(1/2), 84–90.*
13. *Lee, Y. (2016). Association between helicobacter pylori eradication and gastric cancer incidence: A systematic review and meta-analysis. Gastroenterology (New York, N.Y. 1943), 150(5), 1113–1124.e5. DOI: 10.1053/j.gastro.2016.01.028.*
14. *Iizas H; Nanbo A; Nishikawa J; Yoshiyama H. (2012). Epstein Barr virus (EBV)-associated gastric carcinoma. Viruses, 4(12), 3420–3439. DOI: 10.3390/v4123420.*
15. *Zhang, Q., & Peng, C. (2018). Cancer-associated fibroblasts regulate the biological behavior of cancer cells and stroma in gastric cancer. Oncology Letters, 15(1), 691–698. DOI: 10.3892/ol.2017.7385.*
16. *Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. (2015). Global cancer statistics, 2012. CA Cancer J Clin, 65(2), 87–108. doi: 10.3322/caac.21262*
17. *Prashanth, R., & Barsouk, A. (2019). Epidemiology of gastric cancer: global trends, risk factors and prevention. Przeglad Gastroenterologiczny, 14(1), 26–38. DOI: 10.5114/pg.2018.80001*
18. *Chen, Y. C., Fang, W. L., Wang, R. F., Liu, C. A., Yang, M. H., Lo, S. S., ... Huang, K. H. (2016). Clinicopathological Variation of Lauren Classification in Gastric Cancer. Pathol Oncol Res, 22(1), 197–202. DOI: 10.1007/s12253-015-9996-6.*
19. *Hu, B., Hajj, N., Sittler, S., Lammert, N., Barnes, R., & Meloni-Ehrig, A. (2012). Gastric cancer: Classification, histology and application of molecular pathology. J Gastrointest Oncol, 3(3), 251–261. doi: 10.3978/j.issn.2078-6891.2012.021*
20. *Li, Y., Xue, X. W., Luo, Y. F., Wu, H. W., Chen, J., & Zhou, W. X. (2018). Clinicopathologic features of gastric adenocarcinoma based on the revised Lauren's classification. Zhonghua Bing Li Xue Za Zhi, 47(7), 486–491. DOI: 10.3760/cma.j.issn.0529-5807.2018.07.002.*
21. *Miaozhen, Q., Zhou, Y., Zhang, X., Wang, Z., Wang, F., Shao, J., ... Zhang, D. (2014). Lauren classification combined with HER2 status is a better prognostic factor in Chinese gastric cancer patients. BMC Cancer, 14(823). DOI: 10.1186/1471-2407-14-823.*
22. *Zhu ZA, Zhu ZQ, Cai HX, Liu Y. (2012). Reversion of multidrug resistance by SKI-II in SGC7901/DDP cells and exploration of underlying mechanisms. Asian Pac J Cancer Prev, 13(2), 625–631. doi: 10.7314/APJCP.2012.13.2.625*

23. *Chen, W., Zheng, R., Baade, P. D., et al. (2016). Cancer statistics in China, 2015. CA: A Cancer Journal for Clinicians, 66(2), 115–132. doi: 10.3322/caac.21338*
24. *Huang, H., Yang, X-J., & Gao, R. (2016). Research Advances in the Mechanisms of Gastric Cancer Multidrug Resistance. Zhongguo Yi Xue Ke Xue Yuan Xue Bao, 38(6), 739–745. doi: 10.3881/j.issn.1000-503X.2016.06.020*
25. *Cunningham, D., Allum, W. H., Stenning, S. P., et al. (2006). Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. New England Journal of Medicine, 355(1), 11–20. doi: 10.1056/NEJMoa055531*
26. *Catalano, V., Labianca, R., Beretta, G. D., Gatta, G., de Braud, F., & Van Cutsem, E. (2009). Gastric cancer. Critical Reviews in Oncology/Hematology, 71(2), 127–164. doi: 10.1016/j.critrevonc.2009.01.004*
27. *Lippert, T. H., Ruoff, H. J., & Volm, M. (2008). Intrinsic and acquired drug resistance in malignant tumors. The main reason for therapeutic failure. Arzneimittelforschung, 58(6), 261–264. doi: 10.1055/s-0031-1296504*
28. *Wagner, A. D., Grothe, W., Haerting, J., Kleber, G., Grothey, A., & Fleig, W. E. (2006). Chemotherapy in advanced gastric cancer: A systematic review and meta-analysis based on aggregate data. Journal of Clinical Oncology, 24(18), 2903–2909. doi: 10.1200/JCO.2005.05.0245*
29. *Zheng, Y., Zhu, X. Q., & Ren, X. G. (2017). Third-line chemotherapy in advanced gastric cancer: A systematic review and meta-analysis. Medicine, 96(24), e6884. doi: 10.1097/MD.0000000000006884*
30. *Volm, M., & Efferth, T. (2015). Prediction of cancer drug resistance and implications for personalized medicine. Frontiers in Oncology, 5, 282. doi: 10.3389/fonc.2015.00282*
31. *Bunting, K. D. (2002). ABC transporters as phenotypic markers and functional regulators of stem cells. Stem Cells, 20(1), 11–20. doi: 10.1002/stem.200011*
32. *Choi, Y. H., & Yu, A. M. (2014). ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development. Current Pharmaceutical Design, 20(5), 793–807. doi: 10.2174/13816128005140214165212*
33. *Cui, H., Zhang, A. J., Chen, M., & Liu, J. J. (2015). ABC transporter inhibitors in reversing multidrug resistance to chemotherapy. Current Drug Targets, 16(12), 1356–1371. doi: 10.2174/1389450116666150330113506*
34. *Iangcharoen, P., Punfa, W., Yodkeeree, S., et al. (2011). Anti-P-glycoprotein conjugated nanoparticles for targeting drug delivery in cancer treatment. Archives of Pharmacal Research, 34(10), 1679–1689. doi: 10.1007/s12272-011-1012-4*
35. *Wang, Y., Ma, G., Wang, Q., et al. (2013). Involvement of CUL4A in regulation of multidrug resistance to P-gp substrate drugs in breast cancer cells. Molecules, 19(1), 159–176. doi: 10.3390/molecules19010159*
36. *Rocco, A., Compare, D., Liguori, E., et al. (2012). MDR1-P-glycoprotein behaves as an oncofetal protein that promotes cell survival in gastric cancer cells. Laboratory Investigation, 92(10), 1407–1418. doi: 10.1038/labinvest.2012.100*
37. *de Oliveira, J., Felipe, A. V., Neto, R. A., Oshima, C. T., de Souza Silva, M., & Forones, N. M. (2014). Association between ABCB1 immunohistochemical expression and overall survival in gastric cancer patients. Asian Pacific Journal of Cancer Prevention, 15(16), 6935–6938. doi: 10.7314/APJCP.2014.15.16.6935*
38. *Katayama, K., Yoshioka, S., Tsukahara, S., Mitsuhashi, J., & Sugimoto, Y. (2007). Inhibition of the mitogen-activated protein kinase pathway results in the down-regulation of P-glycoprotein. Molecular Cancer Therapeutics, 6(7), 2092–2102. doi: 10.1158/1535-7163.MCT-07-0148*
39. *Bentires-Alj, M., Barbu, V., Fillet, M., et al. (2003). NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene, 22(1), 90–97. doi: 10.1038/sj.onc.1206056*
40. *Mao Z, Zhou J, Luan J, Sheng W, Shen X, & Dong X. (2014). Tamoxifen reduces P-gp-mediated multidrug resistance via inhibiting the PI3K/Akt signaling pathway in ER-negative human gastric cancer cells. Biomedicine & Pharmacotherapy, 68(2), 179–183. DOI: 10.1016/j.biopha.2013.10.003.*

*****